SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immucell (ICCC) - Potential Treatment for Cryptosporidium
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jonathan Rothschild who wrote (28)10/4/1997 8:30:00 PM
From: Jonathan Rothschild   of 46
 
How do you like their SBIR grant of 710 MM for studying traveller's diarhea from NIH. This company knows how to fund their research internally without doing a secondary when their stock is depressed. Market cap of 6 million is a joke. No one takes them seriously. This is the type of stock which explodes if the national press picks up the news and retail investors want a piece. Otherwise it languishes at fire sale prices. Lactoferrin commercialization starts soon. Navy trial results before year end. C. difficile colitis trial went well. Crpto environmental test launched in Europe. They've announced that they're looking for a marketing partner on several fronts. If they get a partner on anyone of them, watch out. Meanwhile, company is selling for close to annual revenues, fully diluted. Find me a similar one in the biotech bargain basement treasure chest.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News